Biotech | April 05, 2022
Lupin signs deal with Alvion for cardiometabolic drugs in Southeast Asia
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
The two-day event will showcase achievements and address issues pertaining to the industry
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
The company inaugurated the new production line at the Bengaluru facility to manufacture Computed Tomography Scanners
Through this new set-up, the company intends to make available, affordable high-quality medical diagnostic imaging equipment across Tier 2, 3, and 4 towns in India
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
There is also a strong synergy between Jubilant and Greencure with respect to OTC portfolio which can be explored for R&D, online acceleration and offline distribution
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Subscribe To Our Newsletter & Stay Updated
